Lonza Signs Manufacturing Deal with Biopharma Firm

Lonza says it has signed a deal to produce therapeutic monoclonal antibody Anthim for biopharmaceutical company Elusys Therapeutics (Pine Brook, NJ). Anthim, which is in late-stage development, can be used to treat anthrax infection. Lonza says it will provide process development services and manufacturing capacity, using its GS Gene Expression System, under the deal. Elusys develops antibody therapeutics for treatment of infectious disease. Elusys has been active in the development of bio-warfare countermeasures since 2001 and has worked with the U.S. government...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers